All In MedTech

Device Trial Radar · NCT07628153

Mindfulness and Biofeedback for Anxiety Disorders

Development of Mindfulness Through Adaptive Biofeedback Methods in the Treatment of Anxiety Disorders: Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 188 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

188

Actual

Start

Jul 11, 2022

Primary completion

Feb 24, 2025

Study completion Feb 24, 2025

Sponsor

Lead sponsor
I.M. Sechenov First Moscow State Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 4, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 19 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized controlled trial compared the effectiveness of a 10-day mindfulness training program using adaptive biofeedback (BFB) versus medication therapy (escitalopram 10 mg/day) versus combined treatment (BFB + medication) in inpatients with anxiety disorders (ICD-10 F40/F41). The primary outcomes were changes in anxiety (Hamilton Anxiety Rating Scale, HARS) and mindfulness (Five Facet Mindfulness Questionnaire, FFMQ) from baseline to post-treatment and at one-month follow-up.

Conditions

  • Anxiety Disorders

Interventions

  • "Reacor" adaptive biofeedback systemDevice

    The Reacor system records physiological parameters (heart rate, EEG alpha rhythm) and converts them into real-time auditory and visual signals. Patients undergo 10 daily 60-minute sessions of adaptive biofeedback training aimed at increasing alpha-rhythm power and heart rate variability, thereby developing self-regulation and mindfulness skills. Each session includes 20 minutes of active training with feedback.

  • Escitalopram 10 mg/dayDrug

    Escitalopram 10 mg orally once daily in the morning, started on day 1 without dose titration. Treatment continued during inpatient stay and through one-month follow-up. Adherence monitored by pill count and daily clinical rounds. Therapy follows clinical recommendations approved by the Ministry of Health of the Russian Federation (level A, certainty 1).

  • Biofeedback plus EscitalopramCombination product

    Participants underwent 10 daily 60 minute biofeedback sessions identical to the BFB group, plus daily oral escitalopram 10 mg. The schedule, procedures, and adherence monitoring were the same as in the respective monotherapy arms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Hamilton Anxiety Rating Scale (HARS) total scoreTime frame: Baseline, immediately after 10 day treatment, and at one month follow up.
  2. Change in Five Facet Mindfulness Questionnaire (FFMQ) total scoreTime frame: Baseline, immediately after 10 day treatment, and at one month follow up.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Psychotherapy of the A.Ya. Kozhevnikov Clinic of Nervous Diseases at the Sechenov University Clinical Center

    Moscow, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.